Emmaus Life Sciences Inc (OTCQX:EMMA) announced that it has received a Medicine Registration Certificate (DRN-10164/23) from the Bahrain National Health Regulatory Authority (NHRA), granting marketing authorization for the commercial distribution and sale of Endari in the Kingdom of Bahrain.
The commercial-stage biopharmaceutical company said Endari, which has also been approved in the US, the United Arab Emirates, Israel, Kuwait, and the State of Qata, is a treatment to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
“We are grateful that Bahrain officials have seen fit to make Endari available to sickle cell patients in the country,” Emmaus Life Sciences CEO Dr Yutaka Niihara said in a statement.
“It furthers our mission to afford increased access to Endari in the Middle East and North Africa region, as well as in India, with their large and underserved sickle cell disease patient populations,” Niihara added.
Torrance, California-based Emmaus Life Sciences is a commercial-stage biopharmaceutical company engaged in the discovery, development, and sales of innovative treatments and therapies, including those in the rare and orphan disease categories.
Contact Sean at sean@proactiveinvestors.com